ONE YEAR. ONE CGM.
Introducing Eversense 365. It’s the only one year CGM, and it’s designed to minimize device frustrations so you can manage your diabetes with one less burden in your way.
Eversense 365 is a long-term solution to the everyday frustrations of traditional, short-term CGMs.
No more constant self-insertions and backup CGMs—Eversense 365 lasts one year.
Take the removable transmitter off and put it back on* without wasting a CGM.
Gentle, silicone-based adhesives are changed daily and cause almost no skin reactions5.
Exceptional accuracy, with almost NO FALSE LOW ALERTS from sleeping on your CGM4.
Click the video below to see how the Eversense 365 CGM system monitors your glucose for a YEAR.
Who Qualifies for Eversense 365?
You could be a candidate for Eversense 365 if:
Pay as little as $199‡
Experience the Eversense 365 CGM system for as low as $199 for a full year. This includes the cost of both CGM sensor and transmitter.‡
One year CGM vs 10-14 days. You do the math.
Eversense 365 is a long-term solution to the everyday frustrations of traditional, short-term CGMs.
Eversense gives you real-time glucose readings through a small sensor that’s placed just under the skin of your upper arm by a healthcare provider. The smart transmitter sits above the sensor, sending glucose data to your app. Want to learn more about the science behind Eversense? Check out our “How Eversense Works” video!
The main difference between Eversense 365 and Eversense E3 is that Eversense 365 lasts for one year.
Eversense 365 is the only CGM that lasts for an entire year - see how we compare!
Download our discussion guide and bring it to your next appointment and talk to your doctor about how Eversense may be a better fit for your diabetes management plan. We will work with you and your healthcare provider to manage your insurance claim.
The tiny sensor is placed just under the skin of your upper arm by a trained healthcare provider. There's a small incision which is then closed with Steri-Strips (which you can remove within a few days) - no stitches involved. Then you're good to go for one year!
* There is no glucose data generated when the transmitter is removed
†Not a guarantee of coverage and payment. A doctor’s prescription is required for Medicare coverage and patients must meet Medicare eligibility coverage criteria. Coverage and payment may be subject to coinsurance, deductible and patient eligibility requirements. Visit http://www.medicare.gov to learn more about Medicare plans and coverage. For additional details, visit Eversense Cost & Insurance
‡ Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility. See website (bit.ly/EversensePass) for more details. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which patient out-of-pocket costs exceed what is detailed in the offer. Eversense E3 is not eligible for the PASS Program.
1. Abbott. (2024) Freestyle Libre 3 User Guide ART49385-001 Rev. A 04/24
2. Dexcom (2024) G7 User Guide AW00078-10 Rev 003 MT-00078-10
3. Senseonics. (2024) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001 Rev A
4. Christiansen MP et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. DIABETES TECHNOLOGY & THERAPEUTICS 2018; 20(3):197-206
5. Deiss, D. et al. (2020). Real-world safety of an implantable continuous glucose sensor over multiple cycles of use: A post-market registry study. Diabetes Technology and Therapeutics, 22(1), 48–52. https://doi.org/10.1089/dia.2019.0159
6. Data on File. Senseonics. Policy Reporter (8/23/2024)
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-365-GBL-0018